Compare AstraZeneca plc (AZN) vs Zillow Group Inc Class C (Z) Price & Performance

AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.

The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.

Zillow Group Inc. (Z) trades at $32.19 with no daily change, reflecting a bearish technical signal amid ongoing class action lawsuits. The company shows improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability, though net margins remain thin at 2.27%. Valuation ratios are elevated with a P/E of 127.4, while analyst consensus targets $57.67, implying significant upside if legal and operational risks subside.

The stock presents a high-risk, high-reward scenario. Positive earnings beats and projected margin expansion to 2.26% in 2026 support bullish fundamentals, but legal overhangs and negative cash flow trends pose near-term headwinds. Institutional sentiment is mixed with 46% buy ratings, suggesting cautious optimism contingent on resolution of litigation and execution on growth initiatives.